Latest Ratios: P/E Ratio 111.9x · EV/EBITDA 18.9x · ROE 6214.7%. (2010–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $468.7B | $405.3B | $315.1B | $274.8B | $287.3B | $240.6B | $179.3B | $131.4B | $142.5B | $155.0B | $102.1B |
| Enterprise Value | $532.6B | $469.2B | $377.4B | $322.1B | $342.3B | $308.4B | $257.9B | $158.6B | $175.5B | $183.1B | $133.9B |
| P/E Ratio → | 111.94 | 96.41 | 74.35 | 56.97 | 24.38 | 20.99 | 39.39 | 16.77 | 25.05 | 29.31 | 17.25 |
| P/S Ratio | 7.66 | 6.63 | 5.59 | 5.06 | 4.95 | 4.28 | 3.91 | 3.95 | 4.35 | 5.49 | 3.98 |
| P/B Ratio | — | — | 93.66 | 26.43 | 16.62 | 15.59 | 13.69 | — | — | 30.42 | 22.03 |
| P/FCF | 26.31 | 22.75 | 17.67 | 12.45 | 11.85 | 10.94 | 10.68 | 10.29 | 11.14 | 16.44 | 15.56 |
| P/OCF | 24.63 | 21.30 | 16.75 | 12.03 | 11.52 | 10.56 | 10.19 | 9.86 | 10.61 | 15.56 | 14.51 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.67 | 6.70 | 5.93 | 5.90 | 5.49 | 5.63 | 4.77 | 5.36 | 6.49 | 5.22 |
| EV / EBITDA | 18.87 | 16.62 | 21.54 | 15.01 | 12.88 | 11.66 | 14.46 | 10.57 | 21.54 | 16.58 | 12.71 |
| EV / EBIT | 26.51 | 49.44 | 57.84 | 38.01 | 21.79 | 20.01 | 44.07 | 15.53 | 26.82 | 20.63 | 14.99 |
| EV / FCF | — | 26.33 | 21.16 | 14.60 | 14.12 | 14.03 | 15.36 | 12.41 | 13.73 | 19.41 | 20.40 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.2% | 70.2% | 70.0% | 62.4% | 70.0% | 69.0% | 66.4% | 77.6% | 76.4% | 75.0% | 77.2% |
| Operating Margin | 32.8% | 32.8% | 16.2% | 23.5% | 31.2% | 31.9% | 24.8% | 39.0% | 19.5% | 33.8% | 36.4% |
| Net Profit Margin | 6.9% | 6.9% | 7.6% | 9.0% | 20.4% | 20.5% | 10.1% | 23.7% | 17.4% | 18.8% | 23.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 6214.7% | 6214.7% | 62.2% | 35.1% | 72.3% | 80.9% | 187.5% | — | — | 109.1% | 138.7% |
| ROA | 3.1% | 3.1% | 3.2% | 3.6% | 8.3% | 7.8% | 3.9% | 10.6% | 8.7% | 7.8% | 10.0% |
| ROIC | 23.9% | 23.9% | 11.1% | 14.7% | 17.5% | 15.4% | 15.4% | 44.7% | 16.6% | 20.6% | 22.0% |
| ROCE | 21.5% | 21.5% | 9.5% | 12.4% | 16.4% | 15.4% | 11.6% | 22.5% | 13.3% | 17.3% | 19.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 20.17 | 5.78 | 3.71 | 5.03 | 6.65 | — | — | 7.33 | 7.95 |
| Debt / EBITDA | 2.45 | 2.45 | 3.87 | 2.80 | 2.41 | 2.93 | 4.88 | 4.47 | 4.95 | 3.38 | 3.50 |
| Net Debt / Equity | — | — | 18.52 | 4.55 | 3.18 | 4.39 | 6.00 | — | — | 5.51 | 6.85 |
| Net Debt / EBITDA | 2.26 | 2.26 | 3.56 | 2.20 | 2.07 | 2.56 | 4.41 | 1.81 | 4.05 | 2.54 | 3.01 |
| Debt / FCF | — | 3.58 | 3.49 | 2.14 | 2.27 | 3.08 | 4.68 | 2.13 | 2.58 | 2.98 | 4.84 |
| Interest Coverage | 3.28 | 3.28 | 2.32 | 3.81 | 7.04 | 6.36 | 2.38 | 5.72 | 4.86 | 7.72 | 8.53 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.67 | 0.67 | 0.66 | 0.87 | 0.96 | 0.79 | 0.84 | 3.18 | 0.98 | 1.28 | 1.65 |
| Quick Ratio | 0.56 | 0.56 | 0.55 | 0.76 | 0.84 | 0.70 | 0.73 | 3.06 | 0.89 | 1.18 | 1.51 |
| Cash Ratio | 0.12 | 0.12 | 0.14 | 0.34 | 0.31 | 0.28 | 0.30 | 2.56 | 0.47 | 0.59 | 0.66 |
| Asset Turnover | — | 0.46 | 0.42 | 0.40 | 0.42 | 0.38 | 0.30 | 0.37 | 0.55 | 0.40 | 0.39 |
| Inventory Turnover | 3.68 | 3.68 | 4.04 | 4.98 | 4.87 | 5.58 | 4.65 | 4.10 | 4.81 | 4.39 | 4.04 |
| Days Sales Outstanding | — | 75.13 | 70.75 | 74.96 | 70.76 | 64.80 | 70.30 | 59.56 | 60.00 | 65.82 | 67.74 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 2.5% | 2.9% | 3.5% | 3.8% | 3.5% | 3.8% | 4.3% | 4.8% | 3.9% | 2.6% | 3.6% |
| Payout Ratio | 275.8% | 275.8% | 257.7% | 216.7% | 84.9% | 80.2% | 167.2% | 80.8% | 98.1% | 77.4% | 62.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.9% | 1.0% | 1.3% | 1.8% | 4.1% | 4.8% | 2.5% | 6.0% | 4.0% | 3.4% | 5.8% |
| FCF Yield | 3.8% | 4.4% | 5.7% | 8.0% | 8.4% | 9.1% | 9.4% | 9.7% | 9.0% | 6.1% | 6.4% |
| Buyback Yield | 0.2% | 0.2% | 0.5% | 0.7% | 0.5% | 0.4% | 0.5% | 0.5% | 8.4% | 0.9% | 5.9% |
| Total Shareholder Yield | 2.7% | 3.1% | 4.0% | 4.6% | 4.0% | 4.2% | 4.8% | 5.3% | 12.3% | 3.6% | 9.5% |
| Shares Outstanding | — | $1.8B | $1.8B | $1.8B | $1.8B | $1.8B | $1.7B | $1.5B | $1.5B | $1.6B | $1.6B |
Includes 30+ ratios · 16 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Bull/bear thesis, analyst target revisions, and earnings execution.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ABBV stock.
AbbVie Inc.'s current P/E ratio is 111.9x. The historical average is 36.4x. This places it at the 100th percentile of its historical range.
AbbVie Inc.'s current EV/EBITDA is 18.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 15.5x.
AbbVie Inc.'s return on equity (ROE) is 6214.7%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 88.4%.
Based on historical data, AbbVie Inc. is trading at a P/E of 111.9x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
AbbVie Inc.'s current dividend yield is 2.48% with a payout ratio of 275.8%.
AbbVie Inc. has 70.2% gross margin and 32.8% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
AbbVie Inc.'s Debt/EBITDA ratio is 2.4x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.
Key Metrics
Top Statement Risk
IRA price negotiation exposure
Metrics are mathematically derived from official filings.
Margin Expansion Masks Earnings Volatility
Gross margin improved to 74.7% in 2026Q2 from 66.7% in 2024Q1, per reported financials, yet net margin swung from 21.3% to 4.7% within two quarters, indicating non-cash charges distort underlying profitability.
The gross margin expansion reflects a favorable mix shift toward Skyrizi and Rinvoq, which carry higher pricing power than Humira. However, the extreme volatility in net margin—ranging from 21.3% in 2026Q2 to 4.7% in 2026Q1—suggests that GAAP earnings are heavily influenced by non-cash items such as amortization and impairments. Investors should focus on operating margin, which has trended upward to 37.9% in 2026Q2, as a more stable indicator of core earning power, though this too may face pressure from IRA negotiations and rebate escalation.
ROIC Recovery Signals Portfolio Transition
ROIC improved to 8.4% in 2026Q2 from 3.4% in 2024Q1, based on reported figures, suggesting the Skyrizi/Rinvoq ramp is beginning to generate returns on the Allergan acquisition, though still below pre-acquisition levels.
The upward trajectory in ROIC from 3.4% to 8.4% over ten quarters indicates that the company is gradually recovering from the capital deployed in the Allergan deal. However, the absolute level remains modest relative to peers like JNJ (19.8%) and MRK (22.0%), implying that AbbVie's capital efficiency is still in a rebuilding phase. The negative ROIC in 2024Q4 (-1.6%) highlights the trough of the Humira erosion, and the subsequent recovery suggests the new immunology portfolio is gaining traction, but sustained improvement will depend on maintaining margins while scaling these assets.
Negative CCC Reflects Supplier Financing Leverage
Cash conversion cycle improved to -532 days in 2026Q2 from -210 days in 2024Q1, as reported in financial statements, driven by extended payables (DPO of 710 days), indicating significant supplier financing leverage.
The deeply negative CCC is a distinctive feature of AbbVie's working capital profile, with DPO stretching to 710 days in 2026Q2 versus 388 days in 2024Q1. This suggests the company is using its scale to delay payments to suppliers, effectively financing operations with interest-free capital. While this boosts cash flow, it may also indicate strained supplier relationships or aggressive payment terms that could reverse. Asset turnover remains low at 0.13, typical for pharma, but the negative CCC partially compensates by reducing the need for external working capital.
High Leverage Persists Despite Cash Flow Strength
Debt-to-EBITDA stood at 8.46 in 2026Q2, down from 17.33 in 2025Q3, per reported data, but interest coverage of 9.01 remains thin relative to the debt load, suggesting refinancing risk if rates rise.
The improvement in D/EBITDA from 17.33 to 8.46 over the past year indicates that EBITDA growth is gradually reducing leverage, but the absolute level remains elevated compared to peers like JNJ (0.59) and MRK (0.96). Interest coverage of 9.01 in 2026Q2 is adequate but vulnerable to rate hikes, especially given the $70.8B debt load. The negative equity complicates traditional D/E analysis, but debt-to-assets of 52.4% reveals the true balance sheet strain. Investors should monitor whether the company can continue deleveraging while funding dividends and acquisitions.
Liquidity Buffer Thins as Cash Declines
Current ratio fell to 0.81 in 2026Q2 from 0.94 in 2024Q1, with cash down to $6.6B from $18.1B, based on balance sheet data, indicating a thinner liquidity cushion against near-term obligations.
The declining current ratio and cash balance suggest that AbbVie is increasingly reliant on operating cash flow to meet short-term obligations, which is typical for a company with negative working capital. However, the quick ratio of 0.69 indicates that inventory is not a major liquidity source, and the company's ability to weather a severe downturn depends on sustained cash generation. The negative CCC provides some buffer, but the combination of high debt and thinning liquidity warrants close monitoring, especially if IRA price negotiations pressure cash flows.
Misapplied ROE Distorts Capital Efficiency
ROE spiked to 6214.7% in 2026Q2, per reported figures, but this is distorted by negative equity from buybacks and impairments, making it an unreliable measure of profitability for AbbVie.
The extreme ROE figure is a classic example of a ratio that loses meaning when equity turns negative. AbbVie's shareholders' equity has deteriorated to -$5.9B, so ROE becomes mathematically inflated and does not reflect operational efficiency. Instead, investors should use ROIC, which at 8.4% in 2026Q2 provides a clearer picture of returns on invested capital, or focus on cash flow metrics like FCF margin (21.8%) to assess value creation. The negative equity also obscures leverage, so debt-to-assets or D/EBITDA are more informative for balance sheet risk.